<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35430934</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1475-6374</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of enzyme inhibition and medicinal chemistry</Title>
          <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ligand-based design and synthesis of <i>N'</i>-Benzylidene-3,4-dimethoxybenzohydrazide derivatives as potential antimicrobial agents; evaluation by <i>in vitro</i>, <i>in vivo, and in silico</i> approaches with SAR studies.</ArticleTitle>
        <Pagination>
          <StartPage>1098</StartPage>
          <EndPage>1119</EndPage>
          <MedlinePgn>1098-1119</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2022.2063282</ELocationID>
        <Abstract>
          <AbstractText>Herein, a series of <i>N'</i>-benzylidene-3,4-dimethoxybenzohydrazide derivatives were designed and synthesised to target the multidrug efflux pump (MATE). The antibacterial activities were screened against <i>S. aureus</i>, <i>Acinetobacter</i>, <i>S. typhi</i>, <i>E. coli</i>, and <i>P. aeruginosa</i>, whereas their antifungal activities were screened against <i>C. albicans</i>. Compounds <b>4a</b>, <b>4h</b>, and <b>4i</b> showed the most promising antibacterial and antifungal activities. Moreover, compounds <b>4h</b> and <b>4i</b> being the broader and superior members regarding their antimicrobial effects were selected to be further evaluated via <i>in vivo</i> testing using biochemical analysis and liver/kidney histological examination. Additionally, molecular docking was carried out to attain further deep insights into the synthesised compounds' binding modes. Also, ADMET studies were performed to investigate the physicochemical/pharmacokinetics features and toxicity parameters of the synthesised derivatives. Finally, a structure-antimicrobial activity relationship study was established to facilitate further structural modifications in the future. HighlightsA series of new <i>N'</i>-benzylidene-3,4-dimethoxybenzohydrazide derivatives were designed and synthesised targeting the multidrug efflux pump (MATE) guided by the pharmacophoric features of the co-crystallized native inhibitor of the target protein.The newly synthesised compounds were assessed through <i>in vitro</i>, <i>in vivo</i>, and <i>in silico</i> approaches.Using the agar well diffusion assay, the antibacterial activities of the synthesised compounds were screened against <i>S. aureus</i>, <i>Acinetobacter</i>, <i>S. typhi</i>, <i>E. coli</i>, and <i>P. aeruginosa</i>, whereas, their antifungal activities were screened against <i>C. albicans</i>.The minimal inhibitory concentration (MIC) and the minimal bactericidal concentration (MBC) of the synthesised compounds were investigated on variable microbial species.Compounds (<b>4h</b> and <b>4i</b>) -as the broader and superior members regarding their antimicrobial effects- were further evaluated via <i>in vivo</i> testing using bio-chemical analysis and liver/kidney histological examination.A molecular docking study and ADMET <i>in silico</i> studies were performed.A structure-antimicrobial activity relationship study was established to facilitate further structural modifications in the future.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ezz Eldin</LastName>
            <ForeName>Rogy R</ForeName>
            <Initials>RR</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Port Said University, Port Said, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saleh</LastName>
            <ForeName>Marwa A</ForeName>
            <Initials>MA</Initials>
            <Identifier Source="ORCID">0000-0003-0767-9864</Identifier>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alotaibi</LastName>
            <ForeName>Mohammad Hayal</ForeName>
            <Initials>MH</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Chemical Technologies, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alsuair</LastName>
            <ForeName>Reem K</ForeName>
            <Initials>RK</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Chemical Technologies, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alzahrani</LastName>
            <ForeName>Yahya A</ForeName>
            <Initials>YA</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Chemical Technologies, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alshehri</LastName>
            <ForeName>Feras A</ForeName>
            <Initials>FA</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Chemical Technologies, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mohamed</LastName>
            <ForeName>Amany F</ForeName>
            <Initials>AF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy and Embryology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hafez</LastName>
            <ForeName>Shaimaa M</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy and Embryology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Althoqapy</LastName>
            <ForeName>Azza Ali</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khirala</LastName>
            <ForeName>Seham K</ForeName>
            <Initials>SK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amin</LastName>
            <ForeName>Mona M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>A F</LastName>
            <ForeName>Yousuf</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>AbdElwahab</LastName>
            <ForeName>Azza H</ForeName>
            <Initials>AH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alesawy</LastName>
            <ForeName>Mohamed S</ForeName>
            <Initials>MS</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Elmaaty</LastName>
            <ForeName>Ayman Abo</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry, Faculty of Pharmacy, Port Said University, Port Said, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Al-Karmalawy</LastName>
            <ForeName>Ahmed A</ForeName>
            <Initials>AA</Initials>
            <Identifier Source="ORCID">0000-0002-8173-6073</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>
        <NlmUniqueID>101150203</NlmUniqueID>
        <ISSNLinking>1475-6366</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000890" MajorTopicYN="Y">Anti-Infective Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000935" MajorTopicYN="N">Antifungal Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002176" MajorTopicYN="N">Candida albicans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011550" MajorTopicYN="N">Pseudomonas aeruginosa</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013211" MajorTopicYN="Y">Staphylococcus aureus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">N'-benzylidene-3,4-dimethoxybenzohydrazide</Keyword>
        <Keyword MajorTopicYN="N">SAR</Keyword>
        <Keyword MajorTopicYN="N">antibacterial</Keyword>
        <Keyword MajorTopicYN="N">antifungal</Keyword>
        <Keyword MajorTopicYN="N">in vitro</Keyword>
        <Keyword MajorTopicYN="N">in vivo</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>5</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35430934</ArticleId>
        <ArticleId IdType="pmc">PMC9037180</ArticleId>
        <ArticleId IdType="doi">10.1080/14756366.2022.2063282</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>de Pauw BE.
What are fungal infections?
Mediterr J Hematol Infect Dis
2011;3:e2011001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3103258</ArticleId>
            <ArticleId IdType="pubmed">21625304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tratrat C, Haroun M, Paparisva A, et al.. 
Design, synthesis and biological evaluation of new substituted 5-benzylideno-2-adamantylthiazol [3, 2-b][1, 2, 4] triazol-6 (5H) ones. Pharmacophore models for antifungal activity. Arab J Chem
2018;11:573–90.</Citation>
        </Reference>
        <Reference>
          <Citation>Mancabelli L, Milani C, Lugli GA, et al.. 
Identification of universal gut microbial biomarkers of common human intestinal diseases by meta-analysis. FEMS Microbiol Ecol
2017;93:fix153.</Citation>
        </Reference>
        <Reference>
          <Citation>Britannica "Bacterial disease" . https://www.britannica.com/science/bacterial-disease.</Citation>
        </Reference>
        <Reference>
          <Citation>El-Shershaby MH, El-Gamal KM, Bayoumi AH, et al.. 
The antimicrobial potential and pharmacokinetic profiles of novel quinoline-based scaffolds: synthesis and in silico mechanistic studies as dual DNA gyrase and DHFR inhibitors. N J Chem
2021;45:13986–4004.</Citation>
        </Reference>
        <Reference>
          <Citation>Lal K, Yadav P, Kumar A, et al. Design, synthesis, characterization, antimicrobial evaluation and molecular modeling studies of some dehydroacetic acid-chalcone-1,2,3-triazole hybrids. Bioorg Chem
2018;77:236–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29421698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El Malah T, Nour HF, Satti AA, et al.. 
Design, synthesis, and antimicrobial activities of 1, 2, 3-triazole glycoside clickamers. Molecules
2020;25:790.</Citation>
        </Reference>
        <Reference>
          <Citation>Woodford N, Ellington MJ.. 
The emergence of antibiotic resistance by mutation. Clin Microbiol Infect
2007;13:5–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17184282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee PR, Lin C.. 
The antibiotic paradox: how the misuse of antibiotics destroys their curative powers. Perspect Biol Med
2003;46:603–4.</Citation>
        </Reference>
        <Reference>
          <Citation>Llor C, Bjerrum L.. 
Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf
2014;5:229–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4232501</ArticleId>
            <ArticleId IdType="pubmed">25436105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abo-Ashour MF, Eldehna WM, George RF, et al.. 
Novel indole-thiazolidinone conjugates: design, synthesis and whole-cell phenotypic evaluation as a novel class of antimicrobial agents. Eur J Med Chem
2018;160:49–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30317025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee C-R, Lee JH, Park M, et al.. 
Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol
2017;7:55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5346588</ArticleId>
            <ArticleId IdType="pubmed">28348979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh H, Thangaraj P, Chakrabarti A.. 
Acinetobacter baumannii: a brief account of mechanisms of multidrug resistance and current and future therapeutic management. J Clin Diagn Res
2013;7:2602–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3879836</ArticleId>
            <ArticleId IdType="pubmed">24392418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciofu O, Tolker-Nielsen T.. 
Tolerance and resistance of Pseudomonas aeruginosa biofilms to antimicrobial agents-how P. aeruginosa can escape antibiotics. Front Microbiol
2019;10:913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6509751</ArticleId>
            <ArticleId IdType="pubmed">31130925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munikrishnappa CS, Suresh Kumar GV, Bhandare RR, et al.. 
Multistep synthesis and screening of heterocyclic tetrads containing furan, pyrazoline, thiazole and triazole (or oxadiazole) as antimicrobial and anticancer agents. J Saudi Chem Soc
2022;26:101447.</Citation>
        </Reference>
        <Reference>
          <Citation>Viegas-Junior C, Danuello A, da Silva Bolzani V, et al.. 
Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem
2007;14:1829–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17627520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barreiro EJ, Fraga CA, Miranda AL, Rodrigues CR.. 
Medicinal chemistry of n-acylhydrazones: novel lead-compounds of analgesic, antiinflammatory and antithrombotic drugs. Química Nova
2002;25:129–48.</Citation>
        </Reference>
        <Reference>
          <Citation>Khalifa MM, Al-Karmalawy AA, Elkaeed EB, et al. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies. J Enzyme Inhib Med Chem
2022;37:299–314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8667898</ArticleId>
            <ArticleId IdType="pubmed">34894955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El‐Helby AGA, Sakr H, Eissa IH, et al.. 
Benzoxazole/benzothiazole‐derived VEGFR‐2 inhibitors: design, synthesis, molecular docking, and anticancer evaluations. Archiv Der Pharmazie
2019;352:1900178.</Citation>
        </Reference>
        <Reference>
          <Citation>Donadio S, Maffioli S, Monciardini P, et al.. 
Antibiotic discovery in the twenty-first century: current trends and future perspectives. J Antibiot
2010;63:423–30.</Citation>
        </Reference>
        <Reference>
          <Citation>Al-Karmalawy AA, Khattab M.. 
Molecular modelling of mebendazole polymorphs as a potential colchicine binding site inhibitor. N J Chem
2020;44:13990–6.</Citation>
        </Reference>
        <Reference>
          <Citation>Kusakizako T, Miyauchi H, Ishitani R, Nureki O.. 
Structural biology of the multidrug and toxic compound extrusion superfamily transporters. Biochim Biophys Acta Biomembr
2020;1862:183154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31866287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verma P, Tiwari M, Tiwari V.. 
Efflux pumps in multidrug-resistant Acinetobacter baumannii: current status and challenges in the discovery of efflux pumps inhibitors. Microb Pathog
2021;152:104766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33545327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmad I, Nawaz N, Dermani FK, et al.. 
Bacterial multidrug efflux proteins: a major mechanism of antimicrobial resistance. Curr Drug Targets
2018;19:1–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27924725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radchenko M, Symersky J, Nie R, Lu M.. 
Structural basis for the blockade of MATE multidrug efflux pumps. Nat Commun
2015;6:1–11.</Citation>
        </Reference>
        <Reference>
          <Citation>Swarupa RG, Mohammed AA.. 
Design, synthesis, antibacterial evaluation and molecular docking studies of some newer benzothiazole containing aryl and alkaryl hydrazides. Chem Biodivers
2021;18:1–15.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang L-H, Qiu X-Y, Liu S-J.. 
Synthesis, characterization and crystal structures of Cobalt(II), Zinc(II) and Cadmium(II) complexes derived from 2-Hydroxy-N'-(pyridin-2-ylmethylene)benzohydrazide with antimicrobial activity. Acta Chimica Slovenica
2019;66:675–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33855539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saini M, Kumar P, Kumar M, et al.. 
Synthesis, in vitro antimicrobial, anticancer evaluation and QSAR studies of N′-(substituted)-4-(butan-2-lideneamino) benzohydrazides. Arabian J Chem
2014;7:448–60.</Citation>
        </Reference>
        <Reference>
          <Citation>Krátký M, Konečná K, Brablíková M, et al. Iodinated 1,2-diacylhydrazines, benzohydrazide-hydrazones and their analogues as dual antimicrobial and cytotoxic agents. Bioorg Med Chem
2021;41:116209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34015704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pradeep K, Narasimhan B, Ramasamy K, et al.. 
Synthesis, antimicrobial, anticancer evaluation and QSAR studies of 2/3-bromo-N0-(substituted benzylidene/3-phenylallylidene)-benzohydrazides. Arab J Chem
2014;10:S3740–S3748.</Citation>
        </Reference>
        <Reference>
          <Citation>Takenouchi T, Munekata E.. 
Amyloid β-peptide-induced inhibition of MTT reduction in PC12h and C1300 neuroblastoma cells: effect of nitroprusside. Peptides
1998;19:365–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9493870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zebbiche Z, Tekin S, Küçükbay H, et al.. 
Synthesis and anticancer properties of novel hydrazone derivatives incorporating pyridine and isatin moieties. Archiv Der Pharmazie
2021;354:2000377.</Citation>
        </Reference>
        <Reference>
          <Citation>Young DH, Shaber SH, Avila-Adame C, et al. Synergistic fungicidal compositions including hydrazone derivatives and copper. Google Patents: 2012.</Citation>
        </Reference>
        <Reference>
          <Citation>Sundaree S, Vaddula BR, Tantak MP, et al.. 
Synthesis and anticancer activity study of indolyl hydrazide–hydrazones. Med Chem Res
2016;25:941–50.</Citation>
        </Reference>
        <Reference>
          <Citation>Rector D, Conder G, Folz S.. 
Preparation of antihelmintic acylhydrazones, method of use and compositions. PCT Int Appl
1987;57.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Q-b, Sun L-y, Gong Z-d, Du Y.. 
Veratric acid inhibits LPS-induced IL-6 and IL-8 production in human gingival fibroblasts. Inflammation
2016;39:237–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26329367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inc., C. C. G. , Molecular operating environment (MOE). Chemical Computing Group Inc 1010 Sherbooke St. West, Suite# 910, Montreal. 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>El Gizawy HA, Boshra SA, Mostafa A, et al.. 
Pimenta dioica (L.) Merr. bioactive constituents exert anti-SARS-CoV-2 and anti-inflammatory activities: molecular docking and dynamics, in vitro, and in vivo studies. Molecules
2021;26:5844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8510437</ArticleId>
            <ArticleId IdType="pubmed">34641388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shoala T, Al-Karmalawy AA, Germoush MO, et al.. 
Nanobiotechnological approaches to enhance potato resistance against Potato Leafroll Virus (PLRV) using glycyrrhizic acid ammonium salt and salicylic acid nanoparticles. Horticulturae
2021;7:402.</Citation>
        </Reference>
        <Reference>
          <Citation>Elebeedy D, Elkhatib WF, Kandeil A, et al.. 
Anti-SARS-CoV-2 activities of tanshinone IIA, carnosic acid, rosmarinic acid, salvianolic acid, baicalein, and glycyrrhetinic acid between computational and in vitro insights. RSC Advances
2021;11:29267–86.</Citation>
        </Reference>
        <Reference>
          <Citation>Zaki AA, Ashour A, Elhady SS, et al.. 
Calendulaglycoside A showing potential activity against SARS-CoV-2 main protease: molecular docking, molecular dynamics, and SAR studies. J Tradit Complement Med
2022;12:16–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8126476</ArticleId>
            <ArticleId IdType="pubmed">34026584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eliaa SG, Al-Karmalawy AA, Saleh RM, Elshal MF.. 
Empagliflozin and doxorubicin synergistically inhibit the survival of triple-negative breast cancer cells via interfering with the mTOR pathway and inhibition of calmodulin: in vitro and molecular docking studies. ACS Pharmacol Transl Sci
2020;3:1330–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7737321</ArticleId>
            <ArticleId IdType="pubmed">33344906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savjani KT, Gajjar AK, Savjani JK.. 
Drug solubility: importance and enhancement techniques. Int Sch Res Notices
2012;2012:1–10.</Citation>
        </Reference>
        <Reference>
          <Citation>Scalbert A, Morand C, Manach C, Rémésy C.. 
Absorption and metabolism of polyphenols in the gut and impact on health. Biomed Pharmacother
2002;56:276–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12224598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thanou M, Verhoef J, Junginger H.. 
Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev
2001;52:117–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11718935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sullins AK, Abdel-Rahman SM.. 
Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatr Drugs
2013;15:93–117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23529866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lipinski CA, Lombardo F, Dominy BW, Feeney PJ.. 
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev
1997;23:3–25.</Citation>
        </Reference>
        <Reference>
          <Citation>Levy DD, Zeiger E, Escobar PA, et al.. 
Recommended criteria for the evaluation of bacterial mutagenicity data (Ames test). Mutat Res Genet Toxicol Environ Mutagen
2019;848:403074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31708073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roy S, Mathew M.. 
Fluid flow modulates electrical activity in cardiac hERG potassium channels. J Biol Chem
2018;293:4289–303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5868271</ArticleId>
            <ArticleId IdType="pubmed">29305421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanguinetti MC.
HERG1 channel agonists and cardiac arrhythmia. Curr Opin Pharmacol
2014;15:22–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3984452</ArticleId>
            <ArticleId IdType="pubmed">24721650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue W, Li X, Ma G, et al.. 
N-thiadiazole-4-hydroxy-2-quinolone-3-carboxamides bearing heteroaromatic rings as novel antibacterial agents: design, synthesis, biological evaluation and target identification. Eur J Med Chem
2020;188:112022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31901744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia B, Ma Y-m, Liu B, et al.. 
Synthesis, antimicrobial activity, structure-activity relationship, and molecular docking studies of indole diketopiperazine alkaloids. Front Chem
2019;7:837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6897290</ArticleId>
            <ArticleId IdType="pubmed">31850323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tranmer M, Elliot M.. 
Multiple linear regression. Cathie Marsh Centre Census Survey Res
2008;5:1–5.</Citation>
        </Reference>
        <Reference>
          <Citation>Jorgensen JH, Hindler JF, Reller LB, Weinstein MP.. 
New consensus guidelines from the clinical and laboratory standards institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria. Clin Infect Dis
2007;44:280–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17173232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tagg J, McGiven A.. 
Assay system for bacteriocins. Appl Microbiol
1971;21:943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC377313</ArticleId>
            <ArticleId IdType="pubmed">4930039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hombach M, Maurer FP, Pfiffner T, et al.. 
Standardization of operator-dependent variables affecting precision and accuracy of the disk diffusion method for antibiotic susceptibility testing. J Clin Microbiol
2015;53:3864–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4652116</ArticleId>
            <ArticleId IdType="pubmed">26468500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez-Tudela J, Barchiesi F, Bille J, et al.. 
Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. Clin Microbiol Infect
2003;9:i–viii.</Citation>
        </Reference>
        <Reference>
          <Citation>Fothergill AW, Antifungal susceptibility testing: clinical laboratory and standards institute (CLSI) methods. In Interactions of yeasts, moulds, and antifungal agents, Springer: 2012; pp 65–74.</Citation>
        </Reference>
        <Reference>
          <Citation>Scudiero DA, Shoemaker RH, Paull KD, et al.. 
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res
1988;48:4827–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3409223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paget G, Barnes J.. 
Toxicity tests. Evaluation of drug activities: pharmacometrics
1964;1:135–65.</Citation>
        </Reference>
        <Reference>
          <Citation>Diehl KH, Hull R, Morton D, et al.. 
A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol
2001;21:15–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11180276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kilkenny C, Browne W, Cuthill IC, et al.. 
Animal research: reporting in vivo experiments: the ARRIVE guidelines. British J Pharmacol
2010;160:1577–9.</Citation>
        </Reference>
        <Reference>
          <Citation>Council NR, Guide for the care and use of laboratory animals. 2010.</Citation>
        </Reference>
        <Reference>
          <Citation>Simmons M, Brick JO, The laboratory mouse: selection and management. The laboratory mouse: selection and management. 1970.</Citation>
        </Reference>
        <Reference>
          <Citation>Ding S-P, Li J-C, Jin C.. 
A mouse model of severe acute pancreatitis induced with caerulein and lipopolysaccharide. World J Gastroenterol
2003;9:584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4621587</ArticleId>
            <ArticleId IdType="pubmed">12632523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ochei JO, Kolhatkar AA, Medical laboratory science: theory and practice. New York: McGraw Hill Education: 2000.</Citation>
        </Reference>
        <Reference>
          <Citation>Sims KL, Darcy TP.. 
A leadership-management training curriculum for pathology residents. Am J Clin Pathol
1997;108:90–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9208984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toora B, Rajagopal G, Measurement of creatinine by Jaffe's reaction-determination of concentration of sodium hydroxide required for maximum color development in standard, urine and protein free filtrate of serum. 2002.</Citation>
        </Reference>
        <Reference>
          <Citation>Nicola N, Guidebook to cytokines and their receptors. Oxford: Oxford University Press: 1994.</Citation>
        </Reference>
        <Reference>
          <Citation>Croft M, Duan W, Choi H, et al.. 
TNF superfamily in inflammatory disease: translating basic insights. Trends Immunol
2012;33:144–152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3299395</ArticleId>
            <ArticleId IdType="pubmed">22169337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sedlak J, Lindsay RH.. 
Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem
1968;25:192–205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4973948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tietez F, Enzymic method for quantitative determination of nanogram amounts of total and oxidized. 1969.</Citation>
        </Reference>
        <Reference>
          <Citation>Banchroft J, Stevens A, Turner D, Theory and practice of histological techniques. New York, London, San Francisco, Tokyo: Churchil Livingstone; 1996.</Citation>
        </Reference>
        <Reference>
          <Citation>Hsu S-M, Raine L, Fanger H.. 
Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem
1981;29:577–580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6166661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed ZSO, Hussein S, Ghandour RA, et al.. 
Evaluation of the effect of methotrexate on the hippocampus, cerebellum, liver, and kidneys of adult male albino rat: histopathological, immunohistochemical and biochemical studies. Acta Histochemica
2021;123:151682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33465564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bland M, An introduction to medical statistics. Oxford: Oxford University Press; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Weinberg SL, Abramowitz SK, Statistics using SPSS: an integrative approach. Cambridge: Cambridge University Press; 2008.</Citation>
        </Reference>
        <Reference>
          <Citation>Zaki AA, Al‐Karmalawy AA, Khodir AE, et al.. 
Isolation of cytotoxic active compounds from Reichardia tingitana with investigation of apoptosis mechanistic induction: in silico, in vitro, and SAR studies. South African J Botany
2022;144:115–123.</Citation>
        </Reference>
        <Reference>
          <Citation>Samra RM, Soliman AF, Zaki AA, et al.. 
Bioassay-guided isolation of a new cytotoxic ceramide from Cyperus rotundus L. South African Journal of Botany
2021;139:210–216.</Citation>
        </Reference>
        <Reference>
          <Citation>Raslan MA, F. Taher R, Al-Karmalawy AA, et al.. 
Cordyline fruticosa (L.) A. Chev. leaves: isolation, HPLC/MS profiling and evaluation of nephroprotective and hepatoprotective activities supported by molecular docking. N J Chem
2021;45:22216–22233.</Citation>
        </Reference>
        <Reference>
          <Citation>Elmaaty AA, Darwish KM, Khattab M, et al.. 
In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins. J Biomol Struct Dyn
2021;30:1–28.</Citation>
        </Reference>
        <Reference>
          <Citation>Aziz MA, Shehab WS, Al-Karmalawy AA, et al.. 
Design, synthesis, biological evaluation, 2D-QSAR modeling, and molecular docking studies of novel 1H-3-indolyl derivatives as significant antioxidants. Int J Mol Sci
2021;22:10396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8508798</ArticleId>
            <ArticleId IdType="pubmed">34638734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diab RT, Abdel-Sami ZK, Abdel-Aal EH, et al.. 
Design and synthesis of a new series of 3,5-disubstituted-1,2,4-oxadiazoles as potential colchicine binding site inhibitors: antiproliferative activity, molecular docking, and SAR studies. N J Chem
2021;45:21657–21669.,</Citation>
        </Reference>
        <Reference>
          <Citation>Mahmoud DB, Bakr MM, Al-karmalawy AA, et al.. 
Scrutinizing the feasibility of nonionic surfactants to form isotropic bicelles of curcumin: a potential antiviral candidate against COVID-19. AAPS PharmSciTech
2021;23:44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8716085</ArticleId>
            <ArticleId IdType="pubmed">34966978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salem MA, Aborehab NM, Al-Karmalawy AA, et al.. 
Potential valorization of edible nuts by-products: exploring the immune-modulatory and antioxidants effects of selected nut shells extracts in relation to their metabolic profiles. Antioxidants
2022;11:462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8944461</ArticleId>
            <ArticleId IdType="pubmed">35326112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahmoud A, Mostafa A, Al-Karmalawy AA, et al.. 
Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies. Heliyon
2021;7:e07962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8426143</ArticleId>
            <ArticleId IdType="pubmed">34518806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soltane R, Chrouda A, Mostafa A, et al.. 
Strong inhibitory activity and action modes of synthetic maslinic acid derivative on highly pathogenic coronaviruses: COVID-19 drug candidate. Pathogens
2021;10:623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8159111</ArticleId>
            <ArticleId IdType="pubmed">34069460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elmaaty AA, Alnajjar R, Hamed MI, et al.. 
Revisiting activity of some glucocorticoids as a potential inhibitor of SARS-CoV-2 main protease: theoretical study. RSC Adv
2021;11:10027–10042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8695394</ArticleId>
            <ArticleId IdType="pubmed">35423530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elmaaty AA, Darwish KM, Chrouda A, et al.. 
In silico and in vitro studies for benzimidazole anthelmintics repurposing as VEGFR-2 antagonists: novel mebendazole-loaded mixed micelles with enhanced dissolution and anticancer activity. ACS Omega
2022;7:875–899.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8757357</ArticleId>
            <ArticleId IdType="pubmed">35036753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Masry R, Al-Karmalawy AA, Alnajjar RA, et al.. 
Newly synthesized series of oxoindole-oxadiazole conjugates as potential anti-SARS-CoV-2 agents: in silico and in vitro studies. N J Chem
2022;46:5078–5090.</Citation>
        </Reference>
        <Reference>
          <Citation>Al-Karmalawy AA, Alnajjar R, Dahab M, et al.. 
Molecular docking and dynamics simulations reveal the potential of anti-HCV drugs to inhibit COVID-19 main protease. Pharm Sci
2021;27(Suppl 1): S109–S121 .</Citation>
        </Reference>
        <Reference>
          <Citation>Al-Karmalawy AA, Dahab MA, Metwaly AM, et al.. 
Molecular docking and dynamics simulation revealed the potential inhibitory activity of ACEIs against SARS-CoV-2 targeting the hACE2 receptor. Front Chem
2021;9:661230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8129187</ArticleId>
            <ArticleId IdType="pubmed">34017819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Demerdash A, Al-Karmalawy AA, Abdel-Aziz TM, et al.. 
Investigating the structure–activity relationship of marine natural polyketides as promising SARS-CoV-2 main protease inhibitors. RSC Advances
2021;11:31339–31363.</Citation>
        </Reference>
        <Reference>
          <Citation>Abdallah AE, Alesawy MS, Eissa SI, et al.. 
Design and synthesis of new 4-(2-nitrophenoxy)benzamide derivatives as potential antiviral agents: molecular modeling and in vitro antiviral screening. N J Chem
2021;45:16557–16571.</Citation>
        </Reference>
        <Reference>
          <Citation>Elebeedy D, Badawy I, Elmaaty AA, et al.. 
In vitro and computational insights revealing the potential inhibitory effect of Tanshinone IIA against influenza A virus. Comp Biol Med
2022;141:105149.</Citation>
        </Reference>
        <Reference>
          <Citation>Taher RF, Al‐Karmalawy AA, Abd El Maksoud AI, et al.. 
Two new flavonoids and anticancer activity of Hymenosporum flavum: in vitro and molecular docking studies. J Herbmed Pharmacol
2021;10:443–458.</Citation>
        </Reference>
        <Reference>
          <Citation>Khattab M, Al‐Karmalawy AA.. 
Revisiting activity of some nocodazole analogues as a potential anticancer drugs using molecular docking and DFT calculations. Front Chem
2021;9:92.</Citation>
        </Reference>
        <Reference>
          <Citation>Al-Karmalawy AA, Farid MM, Mostafa A, et al.. 
Naturally available flavonoid aglycones as potential antiviral drug candidates against SARS-CoV-2. Molecules
2021;26:6559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8587465</ArticleId>
            <ArticleId IdType="pubmed">34770969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hazem RM, Antar SA, Nafea YK, et al.. 
Pirfenidone and vitamin D mitigate renal fibrosis induced by doxorubicin in mice with Ehrlich solid tumor. Life Sciences
2022;288:120185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34861286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghanem A, Al-Karmalawy AA, Abd El Maksoud AI, et al.. 
Rumex Vesicarius L. extract improves the efficacy of doxorubicin in triple-negative breast cancer through inhibiting Bcl2, mTOR, JNK1 and augmenting p21 expression. Inform Med Unlocked
2022;29:100869.</Citation>
        </Reference>
        <Reference>
          <Citation>Mahmoud DB, Ismail WM, Moatasim Y, et al.. 
Delineating a potent antiviral activity of Cuphea ignea extract loaded nano-formulation against SARS-CoV-2: In silico and in vitro studies. J Drug Delivery Sci Technol
2021;66:102845.</Citation>
        </Reference>
        <Reference>
          <Citation>Khattab M, Al-Karmalawy AA.. 
Computational repurposing of benzimidazole anthelmintic drugs as potential colchicine binding site inhibitors. Future Med Chem
2021;13:null–1638.</Citation>
        </Reference>
        <Reference>
          <Citation>Hamed MIA, Darwish KM, Soltane R, et al.. 
β-Blockers bearing hydroxyethylamine and hydroxyethylene as potential SARS-CoV-2 Mpro inhibitors: rational based design, in silico, in vitro, and SAR studies for lead optimization. RSC Adv
2021;11:35536–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Gaber AA, El‐Morsy AM, Sherbiny FF, et al.. 
Pharmacophore‐linked pyrazolo [3, 4‐d] pyrimidines as EGFR‐TK inhibitors: Synthesis, anticancer evaluation, pharmacokinetics, and in silico mechanistic studies. Archiv Der Pharmazie
2021;e2100258.DOI:10.1002/ardp.202100258</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ardp.202100258</ArticleId>
            <ArticleId IdType="pubmed">34467546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Karmalawy A, Ma C, Taghour MS, et al.. 
Design and synthesis of new quinoxaline derivatives as potential histone deacetylase inhibitors targeting hepatocellular carcinoma: in silico, in vitro, and SAR studies . Front Chem
2021;9:648.</Citation>
        </Reference>
        <Reference>
          <Citation>El-Shershaby MH, Ghiaty A, Bayoumi AH, et al.. 
From triazolophthalazines to triazoloquinazolines: a bioisosterism-guided approach toward the identification of novel PCAF inhibitors with potential anticancer activity. Bioorg Med Chem
2021;42:116266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34126285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alesawy MS, Al‐Karmalawy AA, Elkaeed EB, et al. J. A. d. P., Design and discovery of new 1, 2, 4‐triazolo [4, 3‐c] quinazolines as potential DNA intercalators and topoisomerase II inhibitors. Archiv Der Pharmazie
2021;354:e2000237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33226150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daina A, Michielin O, Zoete V.. 
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep
2017;7:42717–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5335600</ArticleId>
            <ArticleId IdType="pubmed">28256516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pires DE, Blundell TL, Ascher DB.. 
pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem
2015;58:4066–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4434528</ArticleId>
            <ArticleId IdType="pubmed">25860834</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35430934</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1475-6374</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of enzyme inhibition and medicinal chemistry</Title>
          <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ligand-based design and synthesis of <i>N'</i>-Benzylidene-3,4-dimethoxybenzohydrazide derivatives as potential antimicrobial agents; evaluation by <i>in vitro</i>, <i>in vivo, and in silico</i> approaches with SAR studies.</ArticleTitle>
        <Pagination>
          <StartPage>1098</StartPage>
          <EndPage>1119</EndPage>
          <MedlinePgn>1098-1119</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2022.2063282</ELocationID>
        <Abstract>
          <AbstractText>Herein, a series of <i>N'</i>-benzylidene-3,4-dimethoxybenzohydrazide derivatives were designed and synthesised to target the multidrug efflux pump (MATE). The antibacterial activities were screened against <i>S. aureus</i>, <i>Acinetobacter</i>, <i>S. typhi</i>, <i>E. coli</i>, and <i>P. aeruginosa</i>, whereas their antifungal activities were screened against <i>C. albicans</i>. Compounds <b>4a</b>, <b>4h</b>, and <b>4i</b> showed the most promising antibacterial and antifungal activities. Moreover, compounds <b>4h</b> and <b>4i</b> being the broader and superior members regarding their antimicrobial effects were selected to be further evaluated via <i>in vivo</i> testing using biochemical analysis and liver/kidney histological examination. Additionally, molecular docking was carried out to attain further deep insights into the synthesised compounds' binding modes. Also, ADMET studies were performed to investigate the physicochemical/pharmacokinetics features and toxicity parameters of the synthesised derivatives. Finally, a structure-antimicrobial activity relationship study was established to facilitate further structural modifications in the future. HighlightsA series of new <i>N'</i>-benzylidene-3,4-dimethoxybenzohydrazide derivatives were designed and synthesised targeting the multidrug efflux pump (MATE) guided by the pharmacophoric features of the co-crystallized native inhibitor of the target protein.The newly synthesised compounds were assessed through <i>in vitro</i>, <i>in vivo</i>, and <i>in silico</i> approaches.Using the agar well diffusion assay, the antibacterial activities of the synthesised compounds were screened against <i>S. aureus</i>, <i>Acinetobacter</i>, <i>S. typhi</i>, <i>E. coli</i>, and <i>P. aeruginosa</i>, whereas, their antifungal activities were screened against <i>C. albicans</i>.The minimal inhibitory concentration (MIC) and the minimal bactericidal concentration (MBC) of the synthesised compounds were investigated on variable microbial species.Compounds (<b>4h</b> and <b>4i</b>) -as the broader and superior members regarding their antimicrobial effects- were further evaluated via <i>in vivo</i> testing using bio-chemical analysis and liver/kidney histological examination.A molecular docking study and ADMET <i>in silico</i> studies were performed.A structure-antimicrobial activity relationship study was established to facilitate further structural modifications in the future.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ezz Eldin</LastName>
            <ForeName>Rogy R</ForeName>
            <Initials>RR</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Port Said University, Port Said, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saleh</LastName>
            <ForeName>Marwa A</ForeName>
            <Initials>MA</Initials>
            <Identifier Source="ORCID">0000-0003-0767-9864</Identifier>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alotaibi</LastName>
            <ForeName>Mohammad Hayal</ForeName>
            <Initials>MH</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Chemical Technologies, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alsuair</LastName>
            <ForeName>Reem K</ForeName>
            <Initials>RK</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Chemical Technologies, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alzahrani</LastName>
            <ForeName>Yahya A</ForeName>
            <Initials>YA</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Chemical Technologies, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alshehri</LastName>
            <ForeName>Feras A</ForeName>
            <Initials>FA</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Chemical Technologies, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mohamed</LastName>
            <ForeName>Amany F</ForeName>
            <Initials>AF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy and Embryology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hafez</LastName>
            <ForeName>Shaimaa M</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy and Embryology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Althoqapy</LastName>
            <ForeName>Azza Ali</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khirala</LastName>
            <ForeName>Seham K</ForeName>
            <Initials>SK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amin</LastName>
            <ForeName>Mona M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>A F</LastName>
            <ForeName>Yousuf</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>AbdElwahab</LastName>
            <ForeName>Azza H</ForeName>
            <Initials>AH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alesawy</LastName>
            <ForeName>Mohamed S</ForeName>
            <Initials>MS</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Elmaaty</LastName>
            <ForeName>Ayman Abo</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry, Faculty of Pharmacy, Port Said University, Port Said, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Al-Karmalawy</LastName>
            <ForeName>Ahmed A</ForeName>
            <Initials>AA</Initials>
            <Identifier Source="ORCID">0000-0002-8173-6073</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>
        <NlmUniqueID>101150203</NlmUniqueID>
        <ISSNLinking>1475-6366</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000890" MajorTopicYN="Y">Anti-Infective Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000935" MajorTopicYN="N">Antifungal Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002176" MajorTopicYN="N">Candida albicans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011550" MajorTopicYN="N">Pseudomonas aeruginosa</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013211" MajorTopicYN="Y">Staphylococcus aureus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">N'-benzylidene-3,4-dimethoxybenzohydrazide</Keyword>
        <Keyword MajorTopicYN="N">SAR</Keyword>
        <Keyword MajorTopicYN="N">antibacterial</Keyword>
        <Keyword MajorTopicYN="N">antifungal</Keyword>
        <Keyword MajorTopicYN="N">in vitro</Keyword>
        <Keyword MajorTopicYN="N">in vivo</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>5</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35430934</ArticleId>
        <ArticleId IdType="pmc">PMC9037180</ArticleId>
        <ArticleId IdType="doi">10.1080/14756366.2022.2063282</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>de Pauw BE.
What are fungal infections?
Mediterr J Hematol Infect Dis
2011;3:e2011001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3103258</ArticleId>
            <ArticleId IdType="pubmed">21625304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tratrat C, Haroun M, Paparisva A, et al.. 
Design, synthesis and biological evaluation of new substituted 5-benzylideno-2-adamantylthiazol [3, 2-b][1, 2, 4] triazol-6 (5H) ones. Pharmacophore models for antifungal activity. Arab J Chem
2018;11:573–90.</Citation>
        </Reference>
        <Reference>
          <Citation>Mancabelli L, Milani C, Lugli GA, et al.. 
Identification of universal gut microbial biomarkers of common human intestinal diseases by meta-analysis. FEMS Microbiol Ecol
2017;93:fix153.</Citation>
        </Reference>
        <Reference>
          <Citation>Britannica "Bacterial disease" . https://www.britannica.com/science/bacterial-disease.</Citation>
        </Reference>
        <Reference>
          <Citation>El-Shershaby MH, El-Gamal KM, Bayoumi AH, et al.. 
The antimicrobial potential and pharmacokinetic profiles of novel quinoline-based scaffolds: synthesis and in silico mechanistic studies as dual DNA gyrase and DHFR inhibitors. N J Chem
2021;45:13986–4004.</Citation>
        </Reference>
        <Reference>
          <Citation>Lal K, Yadav P, Kumar A, et al. Design, synthesis, characterization, antimicrobial evaluation and molecular modeling studies of some dehydroacetic acid-chalcone-1,2,3-triazole hybrids. Bioorg Chem
2018;77:236–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29421698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El Malah T, Nour HF, Satti AA, et al.. 
Design, synthesis, and antimicrobial activities of 1, 2, 3-triazole glycoside clickamers. Molecules
2020;25:790.</Citation>
        </Reference>
        <Reference>
          <Citation>Woodford N, Ellington MJ.. 
The emergence of antibiotic resistance by mutation. Clin Microbiol Infect
2007;13:5–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17184282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee PR, Lin C.. 
The antibiotic paradox: how the misuse of antibiotics destroys their curative powers. Perspect Biol Med
2003;46:603–4.</Citation>
        </Reference>
        <Reference>
          <Citation>Llor C, Bjerrum L.. 
Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf
2014;5:229–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4232501</ArticleId>
            <ArticleId IdType="pubmed">25436105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abo-Ashour MF, Eldehna WM, George RF, et al.. 
Novel indole-thiazolidinone conjugates: design, synthesis and whole-cell phenotypic evaluation as a novel class of antimicrobial agents. Eur J Med Chem
2018;160:49–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30317025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee C-R, Lee JH, Park M, et al.. 
Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol
2017;7:55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5346588</ArticleId>
            <ArticleId IdType="pubmed">28348979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh H, Thangaraj P, Chakrabarti A.. 
Acinetobacter baumannii: a brief account of mechanisms of multidrug resistance and current and future therapeutic management. J Clin Diagn Res
2013;7:2602–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3879836</ArticleId>
            <ArticleId IdType="pubmed">24392418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciofu O, Tolker-Nielsen T.. 
Tolerance and resistance of Pseudomonas aeruginosa biofilms to antimicrobial agents-how P. aeruginosa can escape antibiotics. Front Microbiol
2019;10:913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6509751</ArticleId>
            <ArticleId IdType="pubmed">31130925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munikrishnappa CS, Suresh Kumar GV, Bhandare RR, et al.. 
Multistep synthesis and screening of heterocyclic tetrads containing furan, pyrazoline, thiazole and triazole (or oxadiazole) as antimicrobial and anticancer agents. J Saudi Chem Soc
2022;26:101447.</Citation>
        </Reference>
        <Reference>
          <Citation>Viegas-Junior C, Danuello A, da Silva Bolzani V, et al.. 
Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem
2007;14:1829–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17627520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barreiro EJ, Fraga CA, Miranda AL, Rodrigues CR.. 
Medicinal chemistry of n-acylhydrazones: novel lead-compounds of analgesic, antiinflammatory and antithrombotic drugs. Química Nova
2002;25:129–48.</Citation>
        </Reference>
        <Reference>
          <Citation>Khalifa MM, Al-Karmalawy AA, Elkaeed EB, et al. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies. J Enzyme Inhib Med Chem
2022;37:299–314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8667898</ArticleId>
            <ArticleId IdType="pubmed">34894955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El‐Helby AGA, Sakr H, Eissa IH, et al.. 
Benzoxazole/benzothiazole‐derived VEGFR‐2 inhibitors: design, synthesis, molecular docking, and anticancer evaluations. Archiv Der Pharmazie
2019;352:1900178.</Citation>
        </Reference>
        <Reference>
          <Citation>Donadio S, Maffioli S, Monciardini P, et al.. 
Antibiotic discovery in the twenty-first century: current trends and future perspectives. J Antibiot
2010;63:423–30.</Citation>
        </Reference>
        <Reference>
          <Citation>Al-Karmalawy AA, Khattab M.. 
Molecular modelling of mebendazole polymorphs as a potential colchicine binding site inhibitor. N J Chem
2020;44:13990–6.</Citation>
        </Reference>
        <Reference>
          <Citation>Kusakizako T, Miyauchi H, Ishitani R, Nureki O.. 
Structural biology of the multidrug and toxic compound extrusion superfamily transporters. Biochim Biophys Acta Biomembr
2020;1862:183154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31866287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verma P, Tiwari M, Tiwari V.. 
Efflux pumps in multidrug-resistant Acinetobacter baumannii: current status and challenges in the discovery of efflux pumps inhibitors. Microb Pathog
2021;152:104766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33545327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmad I, Nawaz N, Dermani FK, et al.. 
Bacterial multidrug efflux proteins: a major mechanism of antimicrobial resistance. Curr Drug Targets
2018;19:1–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27924725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radchenko M, Symersky J, Nie R, Lu M.. 
Structural basis for the blockade of MATE multidrug efflux pumps. Nat Commun
2015;6:1–11.</Citation>
        </Reference>
        <Reference>
          <Citation>Swarupa RG, Mohammed AA.. 
Design, synthesis, antibacterial evaluation and molecular docking studies of some newer benzothiazole containing aryl and alkaryl hydrazides. Chem Biodivers
2021;18:1–15.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang L-H, Qiu X-Y, Liu S-J.. 
Synthesis, characterization and crystal structures of Cobalt(II), Zinc(II) and Cadmium(II) complexes derived from 2-Hydroxy-N'-(pyridin-2-ylmethylene)benzohydrazide with antimicrobial activity. Acta Chimica Slovenica
2019;66:675–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33855539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saini M, Kumar P, Kumar M, et al.. 
Synthesis, in vitro antimicrobial, anticancer evaluation and QSAR studies of N′-(substituted)-4-(butan-2-lideneamino) benzohydrazides. Arabian J Chem
2014;7:448–60.</Citation>
        </Reference>
        <Reference>
          <Citation>Krátký M, Konečná K, Brablíková M, et al. Iodinated 1,2-diacylhydrazines, benzohydrazide-hydrazones and their analogues as dual antimicrobial and cytotoxic agents. Bioorg Med Chem
2021;41:116209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34015704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pradeep K, Narasimhan B, Ramasamy K, et al.. 
Synthesis, antimicrobial, anticancer evaluation and QSAR studies of 2/3-bromo-N0-(substituted benzylidene/3-phenylallylidene)-benzohydrazides. Arab J Chem
2014;10:S3740–S3748.</Citation>
        </Reference>
        <Reference>
          <Citation>Takenouchi T, Munekata E.. 
Amyloid β-peptide-induced inhibition of MTT reduction in PC12h and C1300 neuroblastoma cells: effect of nitroprusside. Peptides
1998;19:365–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9493870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zebbiche Z, Tekin S, Küçükbay H, et al.. 
Synthesis and anticancer properties of novel hydrazone derivatives incorporating pyridine and isatin moieties. Archiv Der Pharmazie
2021;354:2000377.</Citation>
        </Reference>
        <Reference>
          <Citation>Young DH, Shaber SH, Avila-Adame C, et al. Synergistic fungicidal compositions including hydrazone derivatives and copper. Google Patents: 2012.</Citation>
        </Reference>
        <Reference>
          <Citation>Sundaree S, Vaddula BR, Tantak MP, et al.. 
Synthesis and anticancer activity study of indolyl hydrazide–hydrazones. Med Chem Res
2016;25:941–50.</Citation>
        </Reference>
        <Reference>
          <Citation>Rector D, Conder G, Folz S.. 
Preparation of antihelmintic acylhydrazones, method of use and compositions. PCT Int Appl
1987;57.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Q-b, Sun L-y, Gong Z-d, Du Y.. 
Veratric acid inhibits LPS-induced IL-6 and IL-8 production in human gingival fibroblasts. Inflammation
2016;39:237–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26329367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inc., C. C. G. , Molecular operating environment (MOE). Chemical Computing Group Inc 1010 Sherbooke St. West, Suite# 910, Montreal. 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>El Gizawy HA, Boshra SA, Mostafa A, et al.. 
Pimenta dioica (L.) Merr. bioactive constituents exert anti-SARS-CoV-2 and anti-inflammatory activities: molecular docking and dynamics, in vitro, and in vivo studies. Molecules
2021;26:5844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8510437</ArticleId>
            <ArticleId IdType="pubmed">34641388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shoala T, Al-Karmalawy AA, Germoush MO, et al.. 
Nanobiotechnological approaches to enhance potato resistance against Potato Leafroll Virus (PLRV) using glycyrrhizic acid ammonium salt and salicylic acid nanoparticles. Horticulturae
2021;7:402.</Citation>
        </Reference>
        <Reference>
          <Citation>Elebeedy D, Elkhatib WF, Kandeil A, et al.. 
Anti-SARS-CoV-2 activities of tanshinone IIA, carnosic acid, rosmarinic acid, salvianolic acid, baicalein, and glycyrrhetinic acid between computational and in vitro insights. RSC Advances
2021;11:29267–86.</Citation>
        </Reference>
        <Reference>
          <Citation>Zaki AA, Ashour A, Elhady SS, et al.. 
Calendulaglycoside A showing potential activity against SARS-CoV-2 main protease: molecular docking, molecular dynamics, and SAR studies. J Tradit Complement Med
2022;12:16–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8126476</ArticleId>
            <ArticleId IdType="pubmed">34026584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eliaa SG, Al-Karmalawy AA, Saleh RM, Elshal MF.. 
Empagliflozin and doxorubicin synergistically inhibit the survival of triple-negative breast cancer cells via interfering with the mTOR pathway and inhibition of calmodulin: in vitro and molecular docking studies. ACS Pharmacol Transl Sci
2020;3:1330–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7737321</ArticleId>
            <ArticleId IdType="pubmed">33344906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savjani KT, Gajjar AK, Savjani JK.. 
Drug solubility: importance and enhancement techniques. Int Sch Res Notices
2012;2012:1–10.</Citation>
        </Reference>
        <Reference>
          <Citation>Scalbert A, Morand C, Manach C, Rémésy C.. 
Absorption and metabolism of polyphenols in the gut and impact on health. Biomed Pharmacother
2002;56:276–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12224598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thanou M, Verhoef J, Junginger H.. 
Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev
2001;52:117–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11718935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sullins AK, Abdel-Rahman SM.. 
Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatr Drugs
2013;15:93–117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23529866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lipinski CA, Lombardo F, Dominy BW, Feeney PJ.. 
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev
1997;23:3–25.</Citation>
        </Reference>
        <Reference>
          <Citation>Levy DD, Zeiger E, Escobar PA, et al.. 
Recommended criteria for the evaluation of bacterial mutagenicity data (Ames test). Mutat Res Genet Toxicol Environ Mutagen
2019;848:403074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31708073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roy S, Mathew M.. 
Fluid flow modulates electrical activity in cardiac hERG potassium channels. J Biol Chem
2018;293:4289–303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5868271</ArticleId>
            <ArticleId IdType="pubmed">29305421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanguinetti MC.
HERG1 channel agonists and cardiac arrhythmia. Curr Opin Pharmacol
2014;15:22–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3984452</ArticleId>
            <ArticleId IdType="pubmed">24721650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue W, Li X, Ma G, et al.. 
N-thiadiazole-4-hydroxy-2-quinolone-3-carboxamides bearing heteroaromatic rings as novel antibacterial agents: design, synthesis, biological evaluation and target identification. Eur J Med Chem
2020;188:112022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31901744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia B, Ma Y-m, Liu B, et al.. 
Synthesis, antimicrobial activity, structure-activity relationship, and molecular docking studies of indole diketopiperazine alkaloids. Front Chem
2019;7:837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6897290</ArticleId>
            <ArticleId IdType="pubmed">31850323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tranmer M, Elliot M.. 
Multiple linear regression. Cathie Marsh Centre Census Survey Res
2008;5:1–5.</Citation>
        </Reference>
        <Reference>
          <Citation>Jorgensen JH, Hindler JF, Reller LB, Weinstein MP.. 
New consensus guidelines from the clinical and laboratory standards institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria. Clin Infect Dis
2007;44:280–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17173232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tagg J, McGiven A.. 
Assay system for bacteriocins. Appl Microbiol
1971;21:943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC377313</ArticleId>
            <ArticleId IdType="pubmed">4930039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hombach M, Maurer FP, Pfiffner T, et al.. 
Standardization of operator-dependent variables affecting precision and accuracy of the disk diffusion method for antibiotic susceptibility testing. J Clin Microbiol
2015;53:3864–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4652116</ArticleId>
            <ArticleId IdType="pubmed">26468500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez-Tudela J, Barchiesi F, Bille J, et al.. 
Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. Clin Microbiol Infect
2003;9:i–viii.</Citation>
        </Reference>
        <Reference>
          <Citation>Fothergill AW, Antifungal susceptibility testing: clinical laboratory and standards institute (CLSI) methods. In Interactions of yeasts, moulds, and antifungal agents, Springer: 2012; pp 65–74.</Citation>
        </Reference>
        <Reference>
          <Citation>Scudiero DA, Shoemaker RH, Paull KD, et al.. 
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res
1988;48:4827–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3409223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paget G, Barnes J.. 
Toxicity tests. Evaluation of drug activities: pharmacometrics
1964;1:135–65.</Citation>
        </Reference>
        <Reference>
          <Citation>Diehl KH, Hull R, Morton D, et al.. 
A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol
2001;21:15–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11180276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kilkenny C, Browne W, Cuthill IC, et al.. 
Animal research: reporting in vivo experiments: the ARRIVE guidelines. British J Pharmacol
2010;160:1577–9.</Citation>
        </Reference>
        <Reference>
          <Citation>Council NR, Guide for the care and use of laboratory animals. 2010.</Citation>
        </Reference>
        <Reference>
          <Citation>Simmons M, Brick JO, The laboratory mouse: selection and management. The laboratory mouse: selection and management. 1970.</Citation>
        </Reference>
        <Reference>
          <Citation>Ding S-P, Li J-C, Jin C.. 
A mouse model of severe acute pancreatitis induced with caerulein and lipopolysaccharide. World J Gastroenterol
2003;9:584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4621587</ArticleId>
            <ArticleId IdType="pubmed">12632523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ochei JO, Kolhatkar AA, Medical laboratory science: theory and practice. New York: McGraw Hill Education: 2000.</Citation>
        </Reference>
        <Reference>
          <Citation>Sims KL, Darcy TP.. 
A leadership-management training curriculum for pathology residents. Am J Clin Pathol
1997;108:90–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9208984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toora B, Rajagopal G, Measurement of creatinine by Jaffe's reaction-determination of concentration of sodium hydroxide required for maximum color development in standard, urine and protein free filtrate of serum. 2002.</Citation>
        </Reference>
        <Reference>
          <Citation>Nicola N, Guidebook to cytokines and their receptors. Oxford: Oxford University Press: 1994.</Citation>
        </Reference>
        <Reference>
          <Citation>Croft M, Duan W, Choi H, et al.. 
TNF superfamily in inflammatory disease: translating basic insights. Trends Immunol
2012;33:144–152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3299395</ArticleId>
            <ArticleId IdType="pubmed">22169337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sedlak J, Lindsay RH.. 
Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem
1968;25:192–205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4973948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tietez F, Enzymic method for quantitative determination of nanogram amounts of total and oxidized. 1969.</Citation>
        </Reference>
        <Reference>
          <Citation>Banchroft J, Stevens A, Turner D, Theory and practice of histological techniques. New York, London, San Francisco, Tokyo: Churchil Livingstone; 1996.</Citation>
        </Reference>
        <Reference>
          <Citation>Hsu S-M, Raine L, Fanger H.. 
Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem
1981;29:577–580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6166661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed ZSO, Hussein S, Ghandour RA, et al.. 
Evaluation of the effect of methotrexate on the hippocampus, cerebellum, liver, and kidneys of adult male albino rat: histopathological, immunohistochemical and biochemical studies. Acta Histochemica
2021;123:151682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33465564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bland M, An introduction to medical statistics. Oxford: Oxford University Press; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Weinberg SL, Abramowitz SK, Statistics using SPSS: an integrative approach. Cambridge: Cambridge University Press; 2008.</Citation>
        </Reference>
        <Reference>
          <Citation>Zaki AA, Al‐Karmalawy AA, Khodir AE, et al.. 
Isolation of cytotoxic active compounds from Reichardia tingitana with investigation of apoptosis mechanistic induction: in silico, in vitro, and SAR studies. South African J Botany
2022;144:115–123.</Citation>
        </Reference>
        <Reference>
          <Citation>Samra RM, Soliman AF, Zaki AA, et al.. 
Bioassay-guided isolation of a new cytotoxic ceramide from Cyperus rotundus L. South African Journal of Botany
2021;139:210–216.</Citation>
        </Reference>
        <Reference>
          <Citation>Raslan MA, F. Taher R, Al-Karmalawy AA, et al.. 
Cordyline fruticosa (L.) A. Chev. leaves: isolation, HPLC/MS profiling and evaluation of nephroprotective and hepatoprotective activities supported by molecular docking. N J Chem
2021;45:22216–22233.</Citation>
        </Reference>
        <Reference>
          <Citation>Elmaaty AA, Darwish KM, Khattab M, et al.. 
In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins. J Biomol Struct Dyn
2021;30:1–28.</Citation>
        </Reference>
        <Reference>
          <Citation>Aziz MA, Shehab WS, Al-Karmalawy AA, et al.. 
Design, synthesis, biological evaluation, 2D-QSAR modeling, and molecular docking studies of novel 1H-3-indolyl derivatives as significant antioxidants. Int J Mol Sci
2021;22:10396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8508798</ArticleId>
            <ArticleId IdType="pubmed">34638734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diab RT, Abdel-Sami ZK, Abdel-Aal EH, et al.. 
Design and synthesis of a new series of 3,5-disubstituted-1,2,4-oxadiazoles as potential colchicine binding site inhibitors: antiproliferative activity, molecular docking, and SAR studies. N J Chem
2021;45:21657–21669.,</Citation>
        </Reference>
        <Reference>
          <Citation>Mahmoud DB, Bakr MM, Al-karmalawy AA, et al.. 
Scrutinizing the feasibility of nonionic surfactants to form isotropic bicelles of curcumin: a potential antiviral candidate against COVID-19. AAPS PharmSciTech
2021;23:44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8716085</ArticleId>
            <ArticleId IdType="pubmed">34966978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salem MA, Aborehab NM, Al-Karmalawy AA, et al.. 
Potential valorization of edible nuts by-products: exploring the immune-modulatory and antioxidants effects of selected nut shells extracts in relation to their metabolic profiles. Antioxidants
2022;11:462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8944461</ArticleId>
            <ArticleId IdType="pubmed">35326112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahmoud A, Mostafa A, Al-Karmalawy AA, et al.. 
Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies. Heliyon
2021;7:e07962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8426143</ArticleId>
            <ArticleId IdType="pubmed">34518806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soltane R, Chrouda A, Mostafa A, et al.. 
Strong inhibitory activity and action modes of synthetic maslinic acid derivative on highly pathogenic coronaviruses: COVID-19 drug candidate. Pathogens
2021;10:623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8159111</ArticleId>
            <ArticleId IdType="pubmed">34069460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elmaaty AA, Alnajjar R, Hamed MI, et al.. 
Revisiting activity of some glucocorticoids as a potential inhibitor of SARS-CoV-2 main protease: theoretical study. RSC Adv
2021;11:10027–10042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8695394</ArticleId>
            <ArticleId IdType="pubmed">35423530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elmaaty AA, Darwish KM, Chrouda A, et al.. 
In silico and in vitro studies for benzimidazole anthelmintics repurposing as VEGFR-2 antagonists: novel mebendazole-loaded mixed micelles with enhanced dissolution and anticancer activity. ACS Omega
2022;7:875–899.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8757357</ArticleId>
            <ArticleId IdType="pubmed">35036753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Masry R, Al-Karmalawy AA, Alnajjar RA, et al.. 
Newly synthesized series of oxoindole-oxadiazole conjugates as potential anti-SARS-CoV-2 agents: in silico and in vitro studies. N J Chem
2022;46:5078–5090.</Citation>
        </Reference>
        <Reference>
          <Citation>Al-Karmalawy AA, Alnajjar R, Dahab M, et al.. 
Molecular docking and dynamics simulations reveal the potential of anti-HCV drugs to inhibit COVID-19 main protease. Pharm Sci
2021;27(Suppl 1): S109–S121 .</Citation>
        </Reference>
        <Reference>
          <Citation>Al-Karmalawy AA, Dahab MA, Metwaly AM, et al.. 
Molecular docking and dynamics simulation revealed the potential inhibitory activity of ACEIs against SARS-CoV-2 targeting the hACE2 receptor. Front Chem
2021;9:661230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8129187</ArticleId>
            <ArticleId IdType="pubmed">34017819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Demerdash A, Al-Karmalawy AA, Abdel-Aziz TM, et al.. 
Investigating the structure–activity relationship of marine natural polyketides as promising SARS-CoV-2 main protease inhibitors. RSC Advances
2021;11:31339–31363.</Citation>
        </Reference>
        <Reference>
          <Citation>Abdallah AE, Alesawy MS, Eissa SI, et al.. 
Design and synthesis of new 4-(2-nitrophenoxy)benzamide derivatives as potential antiviral agents: molecular modeling and in vitro antiviral screening. N J Chem
2021;45:16557–16571.</Citation>
        </Reference>
        <Reference>
          <Citation>Elebeedy D, Badawy I, Elmaaty AA, et al.. 
In vitro and computational insights revealing the potential inhibitory effect of Tanshinone IIA against influenza A virus. Comp Biol Med
2022;141:105149.</Citation>
        </Reference>
        <Reference>
          <Citation>Taher RF, Al‐Karmalawy AA, Abd El Maksoud AI, et al.. 
Two new flavonoids and anticancer activity of Hymenosporum flavum: in vitro and molecular docking studies. J Herbmed Pharmacol
2021;10:443–458.</Citation>
        </Reference>
        <Reference>
          <Citation>Khattab M, Al‐Karmalawy AA.. 
Revisiting activity of some nocodazole analogues as a potential anticancer drugs using molecular docking and DFT calculations. Front Chem
2021;9:92.</Citation>
        </Reference>
        <Reference>
          <Citation>Al-Karmalawy AA, Farid MM, Mostafa A, et al.. 
Naturally available flavonoid aglycones as potential antiviral drug candidates against SARS-CoV-2. Molecules
2021;26:6559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8587465</ArticleId>
            <ArticleId IdType="pubmed">34770969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hazem RM, Antar SA, Nafea YK, et al.. 
Pirfenidone and vitamin D mitigate renal fibrosis induced by doxorubicin in mice with Ehrlich solid tumor. Life Sciences
2022;288:120185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34861286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghanem A, Al-Karmalawy AA, Abd El Maksoud AI, et al.. 
Rumex Vesicarius L. extract improves the efficacy of doxorubicin in triple-negative breast cancer through inhibiting Bcl2, mTOR, JNK1 and augmenting p21 expression. Inform Med Unlocked
2022;29:100869.</Citation>
        </Reference>
        <Reference>
          <Citation>Mahmoud DB, Ismail WM, Moatasim Y, et al.. 
Delineating a potent antiviral activity of Cuphea ignea extract loaded nano-formulation against SARS-CoV-2: In silico and in vitro studies. J Drug Delivery Sci Technol
2021;66:102845.</Citation>
        </Reference>
        <Reference>
          <Citation>Khattab M, Al-Karmalawy AA.. 
Computational repurposing of benzimidazole anthelmintic drugs as potential colchicine binding site inhibitors. Future Med Chem
2021;13:null–1638.</Citation>
        </Reference>
        <Reference>
          <Citation>Hamed MIA, Darwish KM, Soltane R, et al.. 
β-Blockers bearing hydroxyethylamine and hydroxyethylene as potential SARS-CoV-2 Mpro inhibitors: rational based design, in silico, in vitro, and SAR studies for lead optimization. RSC Adv
2021;11:35536–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Gaber AA, El‐Morsy AM, Sherbiny FF, et al.. 
Pharmacophore‐linked pyrazolo [3, 4‐d] pyrimidines as EGFR‐TK inhibitors: Synthesis, anticancer evaluation, pharmacokinetics, and in silico mechanistic studies. Archiv Der Pharmazie
2021;e2100258.DOI:10.1002/ardp.202100258</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ardp.202100258</ArticleId>
            <ArticleId IdType="pubmed">34467546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Karmalawy A, Ma C, Taghour MS, et al.. 
Design and synthesis of new quinoxaline derivatives as potential histone deacetylase inhibitors targeting hepatocellular carcinoma: in silico, in vitro, and SAR studies . Front Chem
2021;9:648.</Citation>
        </Reference>
        <Reference>
          <Citation>El-Shershaby MH, Ghiaty A, Bayoumi AH, et al.. 
From triazolophthalazines to triazoloquinazolines: a bioisosterism-guided approach toward the identification of novel PCAF inhibitors with potential anticancer activity. Bioorg Med Chem
2021;42:116266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34126285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alesawy MS, Al‐Karmalawy AA, Elkaeed EB, et al. J. A. d. P., Design and discovery of new 1, 2, 4‐triazolo [4, 3‐c] quinazolines as potential DNA intercalators and topoisomerase II inhibitors. Archiv Der Pharmazie
2021;354:e2000237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33226150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daina A, Michielin O, Zoete V.. 
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep
2017;7:42717–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5335600</ArticleId>
            <ArticleId IdType="pubmed">28256516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pires DE, Blundell TL, Ascher DB.. 
pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem
2015;58:4066–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4434528</ArticleId>
            <ArticleId IdType="pubmed">25860834</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35430934</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1475-6374</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of enzyme inhibition and medicinal chemistry</Title>
          <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ligand-based design and synthesis of <i>N'</i>-Benzylidene-3,4-dimethoxybenzohydrazide derivatives as potential antimicrobial agents; evaluation by <i>in vitro</i>, <i>in vivo, and in silico</i> approaches with SAR studies.</ArticleTitle>
        <Pagination>
          <StartPage>1098</StartPage>
          <EndPage>1119</EndPage>
          <MedlinePgn>1098-1119</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2022.2063282</ELocationID>
        <Abstract>
          <AbstractText>Herein, a series of <i>N'</i>-benzylidene-3,4-dimethoxybenzohydrazide derivatives were designed and synthesised to target the multidrug efflux pump (MATE). The antibacterial activities were screened against <i>S. aureus</i>, <i>Acinetobacter</i>, <i>S. typhi</i>, <i>E. coli</i>, and <i>P. aeruginosa</i>, whereas their antifungal activities were screened against <i>C. albicans</i>. Compounds <b>4a</b>, <b>4h</b>, and <b>4i</b> showed the most promising antibacterial and antifungal activities. Moreover, compounds <b>4h</b> and <b>4i</b> being the broader and superior members regarding their antimicrobial effects were selected to be further evaluated via <i>in vivo</i> testing using biochemical analysis and liver/kidney histological examination. Additionally, molecular docking was carried out to attain further deep insights into the synthesised compounds' binding modes. Also, ADMET studies were performed to investigate the physicochemical/pharmacokinetics features and toxicity parameters of the synthesised derivatives. Finally, a structure-antimicrobial activity relationship study was established to facilitate further structural modifications in the future. HighlightsA series of new <i>N'</i>-benzylidene-3,4-dimethoxybenzohydrazide derivatives were designed and synthesised targeting the multidrug efflux pump (MATE) guided by the pharmacophoric features of the co-crystallized native inhibitor of the target protein.The newly synthesised compounds were assessed through <i>in vitro</i>, <i>in vivo</i>, and <i>in silico</i> approaches.Using the agar well diffusion assay, the antibacterial activities of the synthesised compounds were screened against <i>S. aureus</i>, <i>Acinetobacter</i>, <i>S. typhi</i>, <i>E. coli</i>, and <i>P. aeruginosa</i>, whereas, their antifungal activities were screened against <i>C. albicans</i>.The minimal inhibitory concentration (MIC) and the minimal bactericidal concentration (MBC) of the synthesised compounds were investigated on variable microbial species.Compounds (<b>4h</b> and <b>4i</b>) -as the broader and superior members regarding their antimicrobial effects- were further evaluated via <i>in vivo</i> testing using bio-chemical analysis and liver/kidney histological examination.A molecular docking study and ADMET <i>in silico</i> studies were performed.A structure-antimicrobial activity relationship study was established to facilitate further structural modifications in the future.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ezz Eldin</LastName>
            <ForeName>Rogy R</ForeName>
            <Initials>RR</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Port Said University, Port Said, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saleh</LastName>
            <ForeName>Marwa A</ForeName>
            <Initials>MA</Initials>
            <Identifier Source="ORCID">0000-0003-0767-9864</Identifier>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alotaibi</LastName>
            <ForeName>Mohammad Hayal</ForeName>
            <Initials>MH</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Chemical Technologies, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alsuair</LastName>
            <ForeName>Reem K</ForeName>
            <Initials>RK</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Chemical Technologies, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alzahrani</LastName>
            <ForeName>Yahya A</ForeName>
            <Initials>YA</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Chemical Technologies, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alshehri</LastName>
            <ForeName>Feras A</ForeName>
            <Initials>FA</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Chemical Technologies, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mohamed</LastName>
            <ForeName>Amany F</ForeName>
            <Initials>AF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy and Embryology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hafez</LastName>
            <ForeName>Shaimaa M</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy and Embryology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Althoqapy</LastName>
            <ForeName>Azza Ali</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khirala</LastName>
            <ForeName>Seham K</ForeName>
            <Initials>SK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amin</LastName>
            <ForeName>Mona M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>A F</LastName>
            <ForeName>Yousuf</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>AbdElwahab</LastName>
            <ForeName>Azza H</ForeName>
            <Initials>AH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alesawy</LastName>
            <ForeName>Mohamed S</ForeName>
            <Initials>MS</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Elmaaty</LastName>
            <ForeName>Ayman Abo</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry, Faculty of Pharmacy, Port Said University, Port Said, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Al-Karmalawy</LastName>
            <ForeName>Ahmed A</ForeName>
            <Initials>AA</Initials>
            <Identifier Source="ORCID">0000-0002-8173-6073</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>
        <NlmUniqueID>101150203</NlmUniqueID>
        <ISSNLinking>1475-6366</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000890" MajorTopicYN="Y">Anti-Infective Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000935" MajorTopicYN="N">Antifungal Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002176" MajorTopicYN="N">Candida albicans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011550" MajorTopicYN="N">Pseudomonas aeruginosa</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013211" MajorTopicYN="Y">Staphylococcus aureus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">N'-benzylidene-3,4-dimethoxybenzohydrazide</Keyword>
        <Keyword MajorTopicYN="N">SAR</Keyword>
        <Keyword MajorTopicYN="N">antibacterial</Keyword>
        <Keyword MajorTopicYN="N">antifungal</Keyword>
        <Keyword MajorTopicYN="N">in vitro</Keyword>
        <Keyword MajorTopicYN="N">in vivo</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>5</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35430934</ArticleId>
        <ArticleId IdType="pmc">PMC9037180</ArticleId>
        <ArticleId IdType="doi">10.1080/14756366.2022.2063282</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>de Pauw BE.
What are fungal infections?
Mediterr J Hematol Infect Dis
2011;3:e2011001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3103258</ArticleId>
            <ArticleId IdType="pubmed">21625304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tratrat C, Haroun M, Paparisva A, et al.. 
Design, synthesis and biological evaluation of new substituted 5-benzylideno-2-adamantylthiazol [3, 2-b][1, 2, 4] triazol-6 (5H) ones. Pharmacophore models for antifungal activity. Arab J Chem
2018;11:573–90.</Citation>
        </Reference>
        <Reference>
          <Citation>Mancabelli L, Milani C, Lugli GA, et al.. 
Identification of universal gut microbial biomarkers of common human intestinal diseases by meta-analysis. FEMS Microbiol Ecol
2017;93:fix153.</Citation>
        </Reference>
        <Reference>
          <Citation>Britannica "Bacterial disease" . https://www.britannica.com/science/bacterial-disease.</Citation>
        </Reference>
        <Reference>
          <Citation>El-Shershaby MH, El-Gamal KM, Bayoumi AH, et al.. 
The antimicrobial potential and pharmacokinetic profiles of novel quinoline-based scaffolds: synthesis and in silico mechanistic studies as dual DNA gyrase and DHFR inhibitors. N J Chem
2021;45:13986–4004.</Citation>
        </Reference>
        <Reference>
          <Citation>Lal K, Yadav P, Kumar A, et al. Design, synthesis, characterization, antimicrobial evaluation and molecular modeling studies of some dehydroacetic acid-chalcone-1,2,3-triazole hybrids. Bioorg Chem
2018;77:236–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29421698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El Malah T, Nour HF, Satti AA, et al.. 
Design, synthesis, and antimicrobial activities of 1, 2, 3-triazole glycoside clickamers. Molecules
2020;25:790.</Citation>
        </Reference>
        <Reference>
          <Citation>Woodford N, Ellington MJ.. 
The emergence of antibiotic resistance by mutation. Clin Microbiol Infect
2007;13:5–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17184282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee PR, Lin C.. 
The antibiotic paradox: how the misuse of antibiotics destroys their curative powers. Perspect Biol Med
2003;46:603–4.</Citation>
        </Reference>
        <Reference>
          <Citation>Llor C, Bjerrum L.. 
Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf
2014;5:229–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4232501</ArticleId>
            <ArticleId IdType="pubmed">25436105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abo-Ashour MF, Eldehna WM, George RF, et al.. 
Novel indole-thiazolidinone conjugates: design, synthesis and whole-cell phenotypic evaluation as a novel class of antimicrobial agents. Eur J Med Chem
2018;160:49–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30317025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee C-R, Lee JH, Park M, et al.. 
Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol
2017;7:55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5346588</ArticleId>
            <ArticleId IdType="pubmed">28348979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh H, Thangaraj P, Chakrabarti A.. 
Acinetobacter baumannii: a brief account of mechanisms of multidrug resistance and current and future therapeutic management. J Clin Diagn Res
2013;7:2602–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3879836</ArticleId>
            <ArticleId IdType="pubmed">24392418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciofu O, Tolker-Nielsen T.. 
Tolerance and resistance of Pseudomonas aeruginosa biofilms to antimicrobial agents-how P. aeruginosa can escape antibiotics. Front Microbiol
2019;10:913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6509751</ArticleId>
            <ArticleId IdType="pubmed">31130925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munikrishnappa CS, Suresh Kumar GV, Bhandare RR, et al.. 
Multistep synthesis and screening of heterocyclic tetrads containing furan, pyrazoline, thiazole and triazole (or oxadiazole) as antimicrobial and anticancer agents. J Saudi Chem Soc
2022;26:101447.</Citation>
        </Reference>
        <Reference>
          <Citation>Viegas-Junior C, Danuello A, da Silva Bolzani V, et al.. 
Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem
2007;14:1829–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17627520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barreiro EJ, Fraga CA, Miranda AL, Rodrigues CR.. 
Medicinal chemistry of n-acylhydrazones: novel lead-compounds of analgesic, antiinflammatory and antithrombotic drugs. Química Nova
2002;25:129–48.</Citation>
        </Reference>
        <Reference>
          <Citation>Khalifa MM, Al-Karmalawy AA, Elkaeed EB, et al. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies. J Enzyme Inhib Med Chem
2022;37:299–314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8667898</ArticleId>
            <ArticleId IdType="pubmed">34894955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El‐Helby AGA, Sakr H, Eissa IH, et al.. 
Benzoxazole/benzothiazole‐derived VEGFR‐2 inhibitors: design, synthesis, molecular docking, and anticancer evaluations. Archiv Der Pharmazie
2019;352:1900178.</Citation>
        </Reference>
        <Reference>
          <Citation>Donadio S, Maffioli S, Monciardini P, et al.. 
Antibiotic discovery in the twenty-first century: current trends and future perspectives. J Antibiot
2010;63:423–30.</Citation>
        </Reference>
        <Reference>
          <Citation>Al-Karmalawy AA, Khattab M.. 
Molecular modelling of mebendazole polymorphs as a potential colchicine binding site inhibitor. N J Chem
2020;44:13990–6.</Citation>
        </Reference>
        <Reference>
          <Citation>Kusakizako T, Miyauchi H, Ishitani R, Nureki O.. 
Structural biology of the multidrug and toxic compound extrusion superfamily transporters. Biochim Biophys Acta Biomembr
2020;1862:183154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31866287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verma P, Tiwari M, Tiwari V.. 
Efflux pumps in multidrug-resistant Acinetobacter baumannii: current status and challenges in the discovery of efflux pumps inhibitors. Microb Pathog
2021;152:104766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33545327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmad I, Nawaz N, Dermani FK, et al.. 
Bacterial multidrug efflux proteins: a major mechanism of antimicrobial resistance. Curr Drug Targets
2018;19:1–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27924725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radchenko M, Symersky J, Nie R, Lu M.. 
Structural basis for the blockade of MATE multidrug efflux pumps. Nat Commun
2015;6:1–11.</Citation>
        </Reference>
        <Reference>
          <Citation>Swarupa RG, Mohammed AA.. 
Design, synthesis, antibacterial evaluation and molecular docking studies of some newer benzothiazole containing aryl and alkaryl hydrazides. Chem Biodivers
2021;18:1–15.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang L-H, Qiu X-Y, Liu S-J.. 
Synthesis, characterization and crystal structures of Cobalt(II), Zinc(II) and Cadmium(II) complexes derived from 2-Hydroxy-N'-(pyridin-2-ylmethylene)benzohydrazide with antimicrobial activity. Acta Chimica Slovenica
2019;66:675–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33855539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saini M, Kumar P, Kumar M, et al.. 
Synthesis, in vitro antimicrobial, anticancer evaluation and QSAR studies of N′-(substituted)-4-(butan-2-lideneamino) benzohydrazides. Arabian J Chem
2014;7:448–60.</Citation>
        </Reference>
        <Reference>
          <Citation>Krátký M, Konečná K, Brablíková M, et al. Iodinated 1,2-diacylhydrazines, benzohydrazide-hydrazones and their analogues as dual antimicrobial and cytotoxic agents. Bioorg Med Chem
2021;41:116209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34015704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pradeep K, Narasimhan B, Ramasamy K, et al.. 
Synthesis, antimicrobial, anticancer evaluation and QSAR studies of 2/3-bromo-N0-(substituted benzylidene/3-phenylallylidene)-benzohydrazides. Arab J Chem
2014;10:S3740–S3748.</Citation>
        </Reference>
        <Reference>
          <Citation>Takenouchi T, Munekata E.. 
Amyloid β-peptide-induced inhibition of MTT reduction in PC12h and C1300 neuroblastoma cells: effect of nitroprusside. Peptides
1998;19:365–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9493870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zebbiche Z, Tekin S, Küçükbay H, et al.. 
Synthesis and anticancer properties of novel hydrazone derivatives incorporating pyridine and isatin moieties. Archiv Der Pharmazie
2021;354:2000377.</Citation>
        </Reference>
        <Reference>
          <Citation>Young DH, Shaber SH, Avila-Adame C, et al. Synergistic fungicidal compositions including hydrazone derivatives and copper. Google Patents: 2012.</Citation>
        </Reference>
        <Reference>
          <Citation>Sundaree S, Vaddula BR, Tantak MP, et al.. 
Synthesis and anticancer activity study of indolyl hydrazide–hydrazones. Med Chem Res
2016;25:941–50.</Citation>
        </Reference>
        <Reference>
          <Citation>Rector D, Conder G, Folz S.. 
Preparation of antihelmintic acylhydrazones, method of use and compositions. PCT Int Appl
1987;57.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Q-b, Sun L-y, Gong Z-d, Du Y.. 
Veratric acid inhibits LPS-induced IL-6 and IL-8 production in human gingival fibroblasts. Inflammation
2016;39:237–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26329367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inc., C. C. G. , Molecular operating environment (MOE). Chemical Computing Group Inc 1010 Sherbooke St. West, Suite# 910, Montreal. 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>El Gizawy HA, Boshra SA, Mostafa A, et al.. 
Pimenta dioica (L.) Merr. bioactive constituents exert anti-SARS-CoV-2 and anti-inflammatory activities: molecular docking and dynamics, in vitro, and in vivo studies. Molecules
2021;26:5844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8510437</ArticleId>
            <ArticleId IdType="pubmed">34641388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shoala T, Al-Karmalawy AA, Germoush MO, et al.. 
Nanobiotechnological approaches to enhance potato resistance against Potato Leafroll Virus (PLRV) using glycyrrhizic acid ammonium salt and salicylic acid nanoparticles. Horticulturae
2021;7:402.</Citation>
        </Reference>
        <Reference>
          <Citation>Elebeedy D, Elkhatib WF, Kandeil A, et al.. 
Anti-SARS-CoV-2 activities of tanshinone IIA, carnosic acid, rosmarinic acid, salvianolic acid, baicalein, and glycyrrhetinic acid between computational and in vitro insights. RSC Advances
2021;11:29267–86.</Citation>
        </Reference>
        <Reference>
          <Citation>Zaki AA, Ashour A, Elhady SS, et al.. 
Calendulaglycoside A showing potential activity against SARS-CoV-2 main protease: molecular docking, molecular dynamics, and SAR studies. J Tradit Complement Med
2022;12:16–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8126476</ArticleId>
            <ArticleId IdType="pubmed">34026584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eliaa SG, Al-Karmalawy AA, Saleh RM, Elshal MF.. 
Empagliflozin and doxorubicin synergistically inhibit the survival of triple-negative breast cancer cells via interfering with the mTOR pathway and inhibition of calmodulin: in vitro and molecular docking studies. ACS Pharmacol Transl Sci
2020;3:1330–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7737321</ArticleId>
            <ArticleId IdType="pubmed">33344906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savjani KT, Gajjar AK, Savjani JK.. 
Drug solubility: importance and enhancement techniques. Int Sch Res Notices
2012;2012:1–10.</Citation>
        </Reference>
        <Reference>
          <Citation>Scalbert A, Morand C, Manach C, Rémésy C.. 
Absorption and metabolism of polyphenols in the gut and impact on health. Biomed Pharmacother
2002;56:276–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12224598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thanou M, Verhoef J, Junginger H.. 
Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev
2001;52:117–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11718935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sullins AK, Abdel-Rahman SM.. 
Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatr Drugs
2013;15:93–117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23529866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lipinski CA, Lombardo F, Dominy BW, Feeney PJ.. 
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev
1997;23:3–25.</Citation>
        </Reference>
        <Reference>
          <Citation>Levy DD, Zeiger E, Escobar PA, et al.. 
Recommended criteria for the evaluation of bacterial mutagenicity data (Ames test). Mutat Res Genet Toxicol Environ Mutagen
2019;848:403074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31708073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roy S, Mathew M.. 
Fluid flow modulates electrical activity in cardiac hERG potassium channels. J Biol Chem
2018;293:4289–303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5868271</ArticleId>
            <ArticleId IdType="pubmed">29305421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanguinetti MC.
HERG1 channel agonists and cardiac arrhythmia. Curr Opin Pharmacol
2014;15:22–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3984452</ArticleId>
            <ArticleId IdType="pubmed">24721650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue W, Li X, Ma G, et al.. 
N-thiadiazole-4-hydroxy-2-quinolone-3-carboxamides bearing heteroaromatic rings as novel antibacterial agents: design, synthesis, biological evaluation and target identification. Eur J Med Chem
2020;188:112022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31901744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia B, Ma Y-m, Liu B, et al.. 
Synthesis, antimicrobial activity, structure-activity relationship, and molecular docking studies of indole diketopiperazine alkaloids. Front Chem
2019;7:837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6897290</ArticleId>
            <ArticleId IdType="pubmed">31850323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tranmer M, Elliot M.. 
Multiple linear regression. Cathie Marsh Centre Census Survey Res
2008;5:1–5.</Citation>
        </Reference>
        <Reference>
          <Citation>Jorgensen JH, Hindler JF, Reller LB, Weinstein MP.. 
New consensus guidelines from the clinical and laboratory standards institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria. Clin Infect Dis
2007;44:280–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17173232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tagg J, McGiven A.. 
Assay system for bacteriocins. Appl Microbiol
1971;21:943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC377313</ArticleId>
            <ArticleId IdType="pubmed">4930039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hombach M, Maurer FP, Pfiffner T, et al.. 
Standardization of operator-dependent variables affecting precision and accuracy of the disk diffusion method for antibiotic susceptibility testing. J Clin Microbiol
2015;53:3864–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4652116</ArticleId>
            <ArticleId IdType="pubmed">26468500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez-Tudela J, Barchiesi F, Bille J, et al.. 
Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. Clin Microbiol Infect
2003;9:i–viii.</Citation>
        </Reference>
        <Reference>
          <Citation>Fothergill AW, Antifungal susceptibility testing: clinical laboratory and standards institute (CLSI) methods. In Interactions of yeasts, moulds, and antifungal agents, Springer: 2012; pp 65–74.</Citation>
        </Reference>
        <Reference>
          <Citation>Scudiero DA, Shoemaker RH, Paull KD, et al.. 
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res
1988;48:4827–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3409223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paget G, Barnes J.. 
Toxicity tests. Evaluation of drug activities: pharmacometrics
1964;1:135–65.</Citation>
        </Reference>
        <Reference>
          <Citation>Diehl KH, Hull R, Morton D, et al.. 
A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol
2001;21:15–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11180276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kilkenny C, Browne W, Cuthill IC, et al.. 
Animal research: reporting in vivo experiments: the ARRIVE guidelines. British J Pharmacol
2010;160:1577–9.</Citation>
        </Reference>
        <Reference>
          <Citation>Council NR, Guide for the care and use of laboratory animals. 2010.</Citation>
        </Reference>
        <Reference>
          <Citation>Simmons M, Brick JO, The laboratory mouse: selection and management. The laboratory mouse: selection and management. 1970.</Citation>
        </Reference>
        <Reference>
          <Citation>Ding S-P, Li J-C, Jin C.. 
A mouse model of severe acute pancreatitis induced with caerulein and lipopolysaccharide. World J Gastroenterol
2003;9:584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4621587</ArticleId>
            <ArticleId IdType="pubmed">12632523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ochei JO, Kolhatkar AA, Medical laboratory science: theory and practice. New York: McGraw Hill Education: 2000.</Citation>
        </Reference>
        <Reference>
          <Citation>Sims KL, Darcy TP.. 
A leadership-management training curriculum for pathology residents. Am J Clin Pathol
1997;108:90–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9208984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toora B, Rajagopal G, Measurement of creatinine by Jaffe's reaction-determination of concentration of sodium hydroxide required for maximum color development in standard, urine and protein free filtrate of serum. 2002.</Citation>
        </Reference>
        <Reference>
          <Citation>Nicola N, Guidebook to cytokines and their receptors. Oxford: Oxford University Press: 1994.</Citation>
        </Reference>
        <Reference>
          <Citation>Croft M, Duan W, Choi H, et al.. 
TNF superfamily in inflammatory disease: translating basic insights. Trends Immunol
2012;33:144–152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3299395</ArticleId>
            <ArticleId IdType="pubmed">22169337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sedlak J, Lindsay RH.. 
Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem
1968;25:192–205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4973948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tietez F, Enzymic method for quantitative determination of nanogram amounts of total and oxidized. 1969.</Citation>
        </Reference>
        <Reference>
          <Citation>Banchroft J, Stevens A, Turner D, Theory and practice of histological techniques. New York, London, San Francisco, Tokyo: Churchil Livingstone; 1996.</Citation>
        </Reference>
        <Reference>
          <Citation>Hsu S-M, Raine L, Fanger H.. 
Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem
1981;29:577–580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6166661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed ZSO, Hussein S, Ghandour RA, et al.. 
Evaluation of the effect of methotrexate on the hippocampus, cerebellum, liver, and kidneys of adult male albino rat: histopathological, immunohistochemical and biochemical studies. Acta Histochemica
2021;123:151682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33465564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bland M, An introduction to medical statistics. Oxford: Oxford University Press; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Weinberg SL, Abramowitz SK, Statistics using SPSS: an integrative approach. Cambridge: Cambridge University Press; 2008.</Citation>
        </Reference>
        <Reference>
          <Citation>Zaki AA, Al‐Karmalawy AA, Khodir AE, et al.. 
Isolation of cytotoxic active compounds from Reichardia tingitana with investigation of apoptosis mechanistic induction: in silico, in vitro, and SAR studies. South African J Botany
2022;144:115–123.</Citation>
        </Reference>
        <Reference>
          <Citation>Samra RM, Soliman AF, Zaki AA, et al.. 
Bioassay-guided isolation of a new cytotoxic ceramide from Cyperus rotundus L. South African Journal of Botany
2021;139:210–216.</Citation>
        </Reference>
        <Reference>
          <Citation>Raslan MA, F. Taher R, Al-Karmalawy AA, et al.. 
Cordyline fruticosa (L.) A. Chev. leaves: isolation, HPLC/MS profiling and evaluation of nephroprotective and hepatoprotective activities supported by molecular docking. N J Chem
2021;45:22216–22233.</Citation>
        </Reference>
        <Reference>
          <Citation>Elmaaty AA, Darwish KM, Khattab M, et al.. 
In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins. J Biomol Struct Dyn
2021;30:1–28.</Citation>
        </Reference>
        <Reference>
          <Citation>Aziz MA, Shehab WS, Al-Karmalawy AA, et al.. 
Design, synthesis, biological evaluation, 2D-QSAR modeling, and molecular docking studies of novel 1H-3-indolyl derivatives as significant antioxidants. Int J Mol Sci
2021;22:10396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8508798</ArticleId>
            <ArticleId IdType="pubmed">34638734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diab RT, Abdel-Sami ZK, Abdel-Aal EH, et al.. 
Design and synthesis of a new series of 3,5-disubstituted-1,2,4-oxadiazoles as potential colchicine binding site inhibitors: antiproliferative activity, molecular docking, and SAR studies. N J Chem
2021;45:21657–21669.,</Citation>
        </Reference>
        <Reference>
          <Citation>Mahmoud DB, Bakr MM, Al-karmalawy AA, et al.. 
Scrutinizing the feasibility of nonionic surfactants to form isotropic bicelles of curcumin: a potential antiviral candidate against COVID-19. AAPS PharmSciTech
2021;23:44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8716085</ArticleId>
            <ArticleId IdType="pubmed">34966978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salem MA, Aborehab NM, Al-Karmalawy AA, et al.. 
Potential valorization of edible nuts by-products: exploring the immune-modulatory and antioxidants effects of selected nut shells extracts in relation to their metabolic profiles. Antioxidants
2022;11:462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8944461</ArticleId>
            <ArticleId IdType="pubmed">35326112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahmoud A, Mostafa A, Al-Karmalawy AA, et al.. 
Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies. Heliyon
2021;7:e07962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8426143</ArticleId>
            <ArticleId IdType="pubmed">34518806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soltane R, Chrouda A, Mostafa A, et al.. 
Strong inhibitory activity and action modes of synthetic maslinic acid derivative on highly pathogenic coronaviruses: COVID-19 drug candidate. Pathogens
2021;10:623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8159111</ArticleId>
            <ArticleId IdType="pubmed">34069460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elmaaty AA, Alnajjar R, Hamed MI, et al.. 
Revisiting activity of some glucocorticoids as a potential inhibitor of SARS-CoV-2 main protease: theoretical study. RSC Adv
2021;11:10027–10042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8695394</ArticleId>
            <ArticleId IdType="pubmed">35423530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elmaaty AA, Darwish KM, Chrouda A, et al.. 
In silico and in vitro studies for benzimidazole anthelmintics repurposing as VEGFR-2 antagonists: novel mebendazole-loaded mixed micelles with enhanced dissolution and anticancer activity. ACS Omega
2022;7:875–899.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8757357</ArticleId>
            <ArticleId IdType="pubmed">35036753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Masry R, Al-Karmalawy AA, Alnajjar RA, et al.. 
Newly synthesized series of oxoindole-oxadiazole conjugates as potential anti-SARS-CoV-2 agents: in silico and in vitro studies. N J Chem
2022;46:5078–5090.</Citation>
        </Reference>
        <Reference>
          <Citation>Al-Karmalawy AA, Alnajjar R, Dahab M, et al.. 
Molecular docking and dynamics simulations reveal the potential of anti-HCV drugs to inhibit COVID-19 main protease. Pharm Sci
2021;27(Suppl 1): S109–S121 .</Citation>
        </Reference>
        <Reference>
          <Citation>Al-Karmalawy AA, Dahab MA, Metwaly AM, et al.. 
Molecular docking and dynamics simulation revealed the potential inhibitory activity of ACEIs against SARS-CoV-2 targeting the hACE2 receptor. Front Chem
2021;9:661230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8129187</ArticleId>
            <ArticleId IdType="pubmed">34017819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Demerdash A, Al-Karmalawy AA, Abdel-Aziz TM, et al.. 
Investigating the structure–activity relationship of marine natural polyketides as promising SARS-CoV-2 main protease inhibitors. RSC Advances
2021;11:31339–31363.</Citation>
        </Reference>
        <Reference>
          <Citation>Abdallah AE, Alesawy MS, Eissa SI, et al.. 
Design and synthesis of new 4-(2-nitrophenoxy)benzamide derivatives as potential antiviral agents: molecular modeling and in vitro antiviral screening. N J Chem
2021;45:16557–16571.</Citation>
        </Reference>
        <Reference>
          <Citation>Elebeedy D, Badawy I, Elmaaty AA, et al.. 
In vitro and computational insights revealing the potential inhibitory effect of Tanshinone IIA against influenza A virus. Comp Biol Med
2022;141:105149.</Citation>
        </Reference>
        <Reference>
          <Citation>Taher RF, Al‐Karmalawy AA, Abd El Maksoud AI, et al.. 
Two new flavonoids and anticancer activity of Hymenosporum flavum: in vitro and molecular docking studies. J Herbmed Pharmacol
2021;10:443–458.</Citation>
        </Reference>
        <Reference>
          <Citation>Khattab M, Al‐Karmalawy AA.. 
Revisiting activity of some nocodazole analogues as a potential anticancer drugs using molecular docking and DFT calculations. Front Chem
2021;9:92.</Citation>
        </Reference>
        <Reference>
          <Citation>Al-Karmalawy AA, Farid MM, Mostafa A, et al.. 
Naturally available flavonoid aglycones as potential antiviral drug candidates against SARS-CoV-2. Molecules
2021;26:6559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8587465</ArticleId>
            <ArticleId IdType="pubmed">34770969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hazem RM, Antar SA, Nafea YK, et al.. 
Pirfenidone and vitamin D mitigate renal fibrosis induced by doxorubicin in mice with Ehrlich solid tumor. Life Sciences
2022;288:120185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34861286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghanem A, Al-Karmalawy AA, Abd El Maksoud AI, et al.. 
Rumex Vesicarius L. extract improves the efficacy of doxorubicin in triple-negative breast cancer through inhibiting Bcl2, mTOR, JNK1 and augmenting p21 expression. Inform Med Unlocked
2022;29:100869.</Citation>
        </Reference>
        <Reference>
          <Citation>Mahmoud DB, Ismail WM, Moatasim Y, et al.. 
Delineating a potent antiviral activity of Cuphea ignea extract loaded nano-formulation against SARS-CoV-2: In silico and in vitro studies. J Drug Delivery Sci Technol
2021;66:102845.</Citation>
        </Reference>
        <Reference>
          <Citation>Khattab M, Al-Karmalawy AA.. 
Computational repurposing of benzimidazole anthelmintic drugs as potential colchicine binding site inhibitors. Future Med Chem
2021;13:null–1638.</Citation>
        </Reference>
        <Reference>
          <Citation>Hamed MIA, Darwish KM, Soltane R, et al.. 
β-Blockers bearing hydroxyethylamine and hydroxyethylene as potential SARS-CoV-2 Mpro inhibitors: rational based design, in silico, in vitro, and SAR studies for lead optimization. RSC Adv
2021;11:35536–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Gaber AA, El‐Morsy AM, Sherbiny FF, et al.. 
Pharmacophore‐linked pyrazolo [3, 4‐d] pyrimidines as EGFR‐TK inhibitors: Synthesis, anticancer evaluation, pharmacokinetics, and in silico mechanistic studies. Archiv Der Pharmazie
2021;e2100258.DOI:10.1002/ardp.202100258</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ardp.202100258</ArticleId>
            <ArticleId IdType="pubmed">34467546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Karmalawy A, Ma C, Taghour MS, et al.. 
Design and synthesis of new quinoxaline derivatives as potential histone deacetylase inhibitors targeting hepatocellular carcinoma: in silico, in vitro, and SAR studies . Front Chem
2021;9:648.</Citation>
        </Reference>
        <Reference>
          <Citation>El-Shershaby MH, Ghiaty A, Bayoumi AH, et al.. 
From triazolophthalazines to triazoloquinazolines: a bioisosterism-guided approach toward the identification of novel PCAF inhibitors with potential anticancer activity. Bioorg Med Chem
2021;42:116266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34126285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alesawy MS, Al‐Karmalawy AA, Elkaeed EB, et al. J. A. d. P., Design and discovery of new 1, 2, 4‐triazolo [4, 3‐c] quinazolines as potential DNA intercalators and topoisomerase II inhibitors. Archiv Der Pharmazie
2021;354:e2000237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33226150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daina A, Michielin O, Zoete V.. 
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep
2017;7:42717–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5335600</ArticleId>
            <ArticleId IdType="pubmed">28256516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pires DE, Blundell TL, Ascher DB.. 
pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem
2015;58:4066–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4434528</ArticleId>
            <ArticleId IdType="pubmed">25860834</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
